The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure.
Acute heart failure
Muscle wasting
Urinary creatinine
Weight loss
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
07
12
2020
received:
24
08
2020
accepted:
01
02
2021
pubmed:
21
3
2021
medline:
26
11
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Muscle wasting and unintentional weight loss (cachexia) have been associated with worse outcomes in heart failure (HF), but timely identification of these adverse phenomena is difficult. Spot urinary creatinine may be an easily accessible marker to assess muscle loss and cachexia. This study investigated the association of urinary creatinine with body composition changes and outcomes in patients with new-onset or worsening HF (WHF). In BIOSTAT-CHF, baseline spot urinary creatinine measurements were available in 2315 patients with new-onset or WHF in an international cohort (index cohort) and a validation cohort of 1431 similar patients from Scotland. Median spot urinary creatinine concentrations were 5.2 [2.7-9.6] mmol/L in the index cohort. Median age was 69 ± 12 years and 73% were men. Lower spot urinary creatinine was associated with older age, lower height and weight, worse renal function, more severe HF, and a higher risk of >5% weight loss from baseline to 9 months (odds ratio = 1.23, 95% CI = 1.09-1.39 per log decrease; P = 0.001). Spot urinary creatinine was associated with Evans criteria of cachexia (OR = 1.26 per log decrease, 95% CI = 1.04-1.49; P = 0.016) and clustered with markers of heart failure severity in hierarchical cluster analyses. Lower urinary creatinine was associated with poorer exercise capacity and quality of life (both P < 0.001) and predicted a higher rate for all-cause mortality [hazard ratio (HR) = 1.27, 95% CI = 1.17-1.38 per log decrease; P < 0.001] and the combined endpoints HF hospitalization or all-cause mortality (HR = 1.23, 95% CI = 1.15-1.31 per log decrease; P < 0.001). Significance was lost after addition of the BIOSTAT risk model. Analyses of the validation cohort yielded similar findings. Lower spot urinary creatinine is associated with smaller body dimensions, renal dysfunction, and more severe HF in patients with new-onset/WHF. Additionally, lower spot urinary creatinine is associated with an increased risk of weight loss and a poorer exercise capacity/quality of life. Urinary creatinine could therefore be a novel, easily obtainable marker to assess (risk of) muscle wasting in HF patients.
Sections du résumé
BACKGROUND
Muscle wasting and unintentional weight loss (cachexia) have been associated with worse outcomes in heart failure (HF), but timely identification of these adverse phenomena is difficult. Spot urinary creatinine may be an easily accessible marker to assess muscle loss and cachexia. This study investigated the association of urinary creatinine with body composition changes and outcomes in patients with new-onset or worsening HF (WHF).
METHODS
In BIOSTAT-CHF, baseline spot urinary creatinine measurements were available in 2315 patients with new-onset or WHF in an international cohort (index cohort) and a validation cohort of 1431 similar patients from Scotland.
RESULTS
Median spot urinary creatinine concentrations were 5.2 [2.7-9.6] mmol/L in the index cohort. Median age was 69 ± 12 years and 73% were men. Lower spot urinary creatinine was associated with older age, lower height and weight, worse renal function, more severe HF, and a higher risk of >5% weight loss from baseline to 9 months (odds ratio = 1.23, 95% CI = 1.09-1.39 per log decrease; P = 0.001). Spot urinary creatinine was associated with Evans criteria of cachexia (OR = 1.26 per log decrease, 95% CI = 1.04-1.49; P = 0.016) and clustered with markers of heart failure severity in hierarchical cluster analyses. Lower urinary creatinine was associated with poorer exercise capacity and quality of life (both P < 0.001) and predicted a higher rate for all-cause mortality [hazard ratio (HR) = 1.27, 95% CI = 1.17-1.38 per log decrease; P < 0.001] and the combined endpoints HF hospitalization or all-cause mortality (HR = 1.23, 95% CI = 1.15-1.31 per log decrease; P < 0.001). Significance was lost after addition of the BIOSTAT risk model. Analyses of the validation cohort yielded similar findings.
CONCLUSIONS
Lower spot urinary creatinine is associated with smaller body dimensions, renal dysfunction, and more severe HF in patients with new-onset/WHF. Additionally, lower spot urinary creatinine is associated with an increased risk of weight loss and a poorer exercise capacity/quality of life. Urinary creatinine could therefore be a novel, easily obtainable marker to assess (risk of) muscle wasting in HF patients.
Identifiants
pubmed: 33742549
doi: 10.1002/jcsm.12690
pmc: PMC8200450
doi:
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-567Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Int Heart J. 2018 Jan 27;59(1):143-148
pubmed: 29332917
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Clin Res Cardiol. 2014 Dec;103(12):976-83
pubmed: 24990450
Am J Clin Nutr. 1983 Mar;37(3):478-94
pubmed: 6829490
Nat Rev Cardiol. 2017 Jun;14(6):323-341
pubmed: 28436486
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
Lancet. 1997 Apr 12;349(9058):1050-3
pubmed: 9107242
Int J Cardiol. 2013 Jan 10;162(2):77-85
pubmed: 21982619
PLoS One. 2014 Nov 17;9(11):e111949
pubmed: 25401694
Clin J Am Soc Nephrol. 2008 Mar;3(2):348-54
pubmed: 18235143
Eur J Heart Fail. 2019 Jan;21(1):112-120
pubmed: 30338883
Cardiology. 2019;142(1):28-36
pubmed: 30893691
Eur J Heart Fail. 2016 Jun;18(6):716-26
pubmed: 27126231
JACC Heart Fail. 2017 May;5(5):359-366
pubmed: 28285121
Am Heart J. 2017 Jun;188:189-195
pubmed: 28577676
Atherosclerosis. 2009 Dec;207(2):534-40
pubmed: 19535078
Eur Heart J. 2013 Feb;34(7):512-9
pubmed: 23178647
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2095-103
pubmed: 25381342
Clin J Am Soc Nephrol. 2017 May 8;12(5):817-824
pubmed: 28476951
Int J Cardiol. 2018 Feb 15;253:84-90
pubmed: 29306478
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Int J Cardiol. 2014 Jan 15;171(1):49-55
pubmed: 24331120
Diabetes Care. 2013 Jun;36(6):1489-94
pubmed: 23300289
J Am Coll Cardiol. 2014 Mar 4;63(8):778-85
pubmed: 24315906
ESC Heart Fail. 2017 Nov;4(4):492-498
pubmed: 29154428
Am J Clin Nutr. 1996 Jun;63(6):863-9
pubmed: 8644679
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):555-567
pubmed: 33742549
PLoS One. 2015 Sep 09;10(9):e0137460
pubmed: 26353117
Eur Heart J. 2008 Nov;29(21):2641-50
pubmed: 18819960
Circulation. 2010 Mar 23;121(11):1295-303
pubmed: 20212276
Eur J Heart Fail. 2019 Jun;21(6):732-743
pubmed: 30843353
Eur J Heart Fail. 2017 May;19(5):627-634
pubmed: 28247565
Eur J Heart Fail. 2015 Apr;17(4):424-33
pubmed: 25704364
Am Heart J. 2007 Jan;153(1):74-81
pubmed: 17174642
JACC Heart Fail. 2018 Feb;6(2):143-152
pubmed: 29413370
Clin J Am Soc Nephrol. 2012 Apr;7(4):595-603
pubmed: 22383750